Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade

2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherapy.

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.